1 citations
,
June 2001 in “Annals of Internal Medicine” Troglitazone increases subcutaneous fat in lipodystrophy patients.
11 citations
,
March 2024 in “Current Issues in Molecular Biology” Ginsenoside compound K shows promise for treating metabolic diseases like diabetes and obesity.
13 citations
,
May 2011 in “Bioorganic & Medicinal Chemistry” Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
December 2023 in “PubMed” Metformin and liraglutide improved symptoms of HAIR-AN syndrome in a child.
May 2026 in “Journal of Medicinal Chemistry” dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.
43 citations
,
August 2010 in “Expert Opinion on Investigational Drugs” Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.
28 citations
,
November 2009 in “European Journal of Neuroscience” Progesterone and allopregnanolone increase glycine release in rat brain cells.
15 citations
,
January 2024 in “Chemical Engineering Journal”
33 citations
,
October 2013 in “Journal of The American Academy of Dermatology” Pioglitazone usually doesn't effectively treat or cure lichen planopilaris.
16 citations
,
November 2018 in “Medicinal Chemistry” The compound GD-23 may reduce anxiety like diazepam by targeting the TSPO receptor.
April 2019 in “Journal of the Endocrine Society” Androgens and estrogens are crucial for insulin secretion in males.
68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.
November 2025 in “Journal of Diabetes Investigation” Dapagliflozin improved blood sugar control in a man with Werner syndrome without side effects.
1 citations
,
October 2005 in “Experimental and Clinical Endocrinology & Diabetes” Allopregnanolone and opioids together reduce stress hormone responses during pregnancy.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
October 2024 in “Scientific Reports” OXTR agonists may promote hair growth and be effective for treating hair loss.
November 2025 in “Scientia Pharmaceutica” Injectable biostimulators can improve skin by boosting collagen and fat cell activity, but more research is needed to confirm their safety and effectiveness.
1 citations
,
January 2025 in “American Journal of Translational Research” PPARα agonists may help treat alopecia areata by reducing inflammation.
5 citations
,
January 2025 in “Burns & Trauma” PPAR activation can improve diabetic wound healing by enhancing blood vessel function.
January 2026 in “Skin Appendage Disorders” Hair shedding is common in GLP-1 users, affecting treatment adherence.
1 citations
,
January 2013 Bimatoprost treats glaucoma and promotes hair growth, with potential for more medical uses.
100 citations
,
May 2003 in “Journal of Neuroscience” Neuroactive steroids affect cocaine's rewarding effects through the ς1 receptor.
52 citations
,
May 2011 in “Journal of Neuroendocrinology” PEA boosts allopregnanolone production and reduces oxidative stress in brain cells.
6 citations
,
February 2023 in “Journal of nanobiotechnology” The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
December 2025 in “Current Issues in Molecular Biology” New steroid compounds may help with hormonal therapy and have potential benefits for glucose disorders, but more research is needed.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
January 2017 in “Open Journal of Endocrine and Metabolic Diseases” The document concludes that managing Dunnigan-Type Familial Partial Lipodystrophy involves treating associated health issues and using medications like metformin and leptin replacement.
23 citations
,
December 2008 in “Current medicinal chemistry” Stimulating sensory neurons can increase IGF-I production, which may help treat various diseases and improve tissue health.
July 2022 in “Journal of Investigative Dermatology” Blocking DPP4 can help activate hair growth and improve hair regeneration.